Coya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA) released its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14, Zacks reports.

Coya Therapeutics Trading Down 1.7 %

Coya Therapeutics stock traded down $0.11 during trading hours on Tuesday, reaching $6.74. 3,384 shares of the stock were exchanged, compared to its average volume of 96,359. The company has a market cap of $112.54 million, a P/E ratio of -10.36 and a beta of 0.31. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.42. The stock has a 50 day moving average of $6.29 and a two-hundred day moving average of $6.48.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th. D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.